Pre-made Vudalimab benchmark antibody ( Bispecific Mixed mAb and scFv, anti-CTLA4/CTLA-4;PDCD1/PD-1 therapeutic antibody, Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3;CD279/SLEB2/hPD-1/hPD-l/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-631

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-631 Category Tags ,

Product Details

Pre-Made Vudalimab biosimilar, Bispecific Mixed mAb and scFv, Anti-CTLA4/CTLA-4;PDCD1/PD-1 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3;CD279/SLEB2/hPD-1/hPD-l/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vudalimab (formerly XmAb 20717 or XmAb 717) is a bispecific antibody being developed by Xencor, for the treatment of solid tumours. Xencor is using its Xtend Fc domain technology (a part of Xencor’s proprietary XmAb? technology) that increases binding affinity to the receptor FcRn.

Products Name (INN Index)

Pre-Made Vudalimab biosimilar, Bispecific Mixed mAb and scFv, Anti-CTLA4/CTLA-4;PDCD1/PD-1 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3;CD279/SLEB2/hPD-1/hPD-l/hSLE1 therapeutic antibody

INN Name

Vudalimab

Target

CTLA4,PDCD1

Format

Bispecific Mixed mAb and scFv

Derivation

Bispecific antibody

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa,Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Active

100% SI Structure

None;None

99% SI Structure

None;None

95-98% SI Structure

5tru:HL/5xj3:DE/6jc2:HL/6rp8:hl;None

Year Proposed

2020

Companies

Xencor

Conditions Approved

NA

Conditions Active

Solid tumours

Conditions Discontinued

NA

Development Tech

XmAb? bispecific platformna (For heterodimer, E357Q/S364K-L368D/K370S; For purification with PI, N208D in CH1, Q295E in CH2, and N384D, Q418E, and N421D in CH3.)

Previous Name

NA

Gm Offical Target Name

CTLA4,PDCD1

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide